Home » Newsletters » BioWorld Science

BioWorld Science

March 3, 2000

View Archived Issues

Intensive therapy offers persistent benefits in type I diabetes

Large valsartan trial reaches enrollment objectives

Alexion makes significant progress over past six months in various development programs

Vertex enters genomic partnership with Incyte

IL-4 gene therapy studied in malignant glioma

Rebif long-term data confirm dose-related efficacy; Ares-Serono to enhance labeling

CryoLife and Viragen enter cancer therapy collaboration

Ampakine-like compounds and their use described by Lilly

Pharmachemie presents new water-soluble tin compounds with excellent antitumor activity

Guilford to develop novel propofol prodrug discovered by ProQuest

MMP inhibitors from Warner-Lambert particularly active against MMP-2, MMP-3 and MMP-13

International team provides new insight into the mechanics of HIV infection

Pharmaceutically useful neuroprotective agents emerge from R&D at Cambridge NeuroScience

ADIR's new MMP inhibitors particularly useful for cancer, rheumatoid arthritis

U.S./Russian investigators present anesthetics with useful hypometabolic, cardiovascular effects

Estrogen protects against brain damage from ischemic insult in female rats

New vitamin D4 metabolite claimed by Bone Care for vitamin D-deficient states

Schedule-dependent antitumor activity demonstrated for new modified steroidal lactams

Induction therapy with daclizumab in cardiac transplant recipients safe and effective

Actonel to be approved in Europe for Rx of postmenopausal osteoporosis

EpiGenesis and Taisho sign binding letter of intent for EPI-2010

Potent factor XIIIa inhibitor synthesized from naturally occurring cyclopropenones

Collaboration between Novartis and Emisphere extended to include second compound

Progenics announces important discoveries related to HIV fusion inhibitors

Triapine anticancer therapy completes phase I trial

Novantrone moves one step closer to approval for MS

Noven successfully completes phase II study of MethyPatch for treatment of ADHD

Popular Stories

23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema
BioWorld
Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...